What question did this study set out to answer?

To investigate the impact of niacin dosage on immune response in glioblastoma patients undergoing standard treatment.

February 6, 2026Neurology Neuroimmunology & Neuroinflammation0 citationsOpen Access

Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma

CPCandice C. PoonUniversity of Calgary KHKathleen M. HagenUniversity of Calgary SSSusobhan SarkarUniversity of Calgary

Key Points

To investigate the impact of niacin dosage on immune response in glioblastoma patients undergoing standard treatment.
Conducted a Phase I dose-escalation clinical trial
Included participants with newly diagnosed glioblastoma
Administered niacin alongside standard of care treatments
Niacin dose escalation appeared to modulate immune responses
Findings support the need for further investigation into niacin's therapeutic potential
No comparison group limits the scope of evidence

Abstract

This study provides Class IV evidence that niacin dose escalation modulates immune response in patients with glioblastoma treated with standard of care, including maximal safe resection, concurrent radiation and temozolomide, and adjuvant temozolomide administration. This is a Class IV study because it is an open-label trial with no blinding or comparison group.

问 AI

Bookmark

View Full Paper

Cite This Study

Poon et al. (Tue,) studied this question.

synapsesocial.com/papers/698584b78f7c464f23008263 https://doi.org/https://doi.org/10.1212/nxi.0000000000200530

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

问 AI

Bookmark

View Full Paper